Roth Capital Initiates Coverage on Alnylam Pharmaceuticals (ALNY) with a Buy
More News related to ALNY
- Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting
- Alnylam Pharma (ALNY) Posts Q3 adj.-Loss of $0.23, Beats by 1c
- Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Alnylam Pharma (ALNY) Advances to RNAi Landmark Stage of Landmark Roche Alliance
- Alnylam and Roche Advance RNAi Therapeutic Collaboration Phase of Landmark 2007 Alliance
Roth Capital initiates coverage on Alnylam Pharmaceuticals (Nasdaq: ALNY) with a Buy. Price target $26.
To see more analyst ratings on ALNY Click Here.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi).
Related Categories
New CoverageStocks Mentioned
-0.27Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
